Epigallocatechin gallate (EGCG) stands out as a kinase inhibitor that could trigger compensatory cellular responses, leading to the activation of proteins through alternative pathways. Similarly, curcumin, with its broad-reaching influence on protein kinases, can adjust the phosphorylation landscape within the cell, potentially affecting proteins associated with C17orf47's functional network. Resveratrol, a sirtuin activator, exerts its effects by initiating changes in gene expression patterns, which could entail upregulation of proteins inclusive of C17orf47. Sodium butyrate operates through inhibition of histone deacetylases, leading to an enriched expression of genes, and by extension, could contribute to increased levels of proteins such as C17orf47. Kenpaullone and lithium chloride, both targeting glycogen synthase kinase-3 (GSK-3), alter phosphorylation cascades that could impinge upon proteins within the orbit of C17orf47's influence.
Further adding to this chemical diversity, compounds like U0126 and PD98059, which selectively inhibit MEK, might prompt cellular mechanisms to activate alternative routes of signaling, with downstream effects on proteins including C17orf47. LY294002's inhibition of PI3K and SP600125's blockage of JNK signaling may similarly recalibrate cellular pathways, with potential repercussions for the modulation of C17orf47. Y-27632, a Rho-associated protein kinase inhibitor, could induce changes in cytoskeletal organization, thereby potentially affecting the activity of proteins like C17orf47, which may be linked to such structural dynamics. Collectively, these compounds, though not directly interacting with C17orf47, are poised to influence the protein's state of activity by navigating through the intricate web of cellular signaling, either by modulating gene expression, altering protein stability, or by affecting the phosphorylation status of proteins within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG can inhibit certain protein kinases, potentially leading to the activation of compensatory pathways that may include protein activation related to C17orf47. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Known to modulate various signaling pathways, curcumin can alter protein kinase activity, which may affect the phosphorylation state and activity of C17orf47. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Sirtuin activator that can lead to changes in chromatin structure and gene expression, possibly affecting C17orf47 expression levels. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
As a histone deacetylase inhibitor, this compound can increase gene expression, potentially raising the levels of proteins like C17orf47. | ||||||
Kenpaullone | 142273-20-9 | sc-200643 sc-200643A sc-200643B sc-200643C | 1 mg 5 mg 10 mg 25 mg | $61.00 $153.00 $231.00 $505.00 | 1 | |
Inhibits glycogen synthase kinase-3 (GSK-3), potentially altering the phosphorylation status of substrates related to pathways that affect C17orf47 activity. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Inhibits GSK-3, which may lead to altered phosphorylation patterns that could include those associated with C17orf47. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
Another GSK-3 inhibitor, potentially affecting the phosphorylation and thus the activity of C17orf47. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
Inhibits MEK, which may lead to the activation of alternative pathways that can act upon C17orf47. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, potentially affecting downstream signaling pathways that can modulate C17orf47 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
Inhibits JNK, which could lead to the activation of alternative signaling routes that impact C17orf47. | ||||||